Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17
HOS-134010 · Präparat HOS-097520
Co-administration with Genvoya may increase dabigatran plasma concentrations with similar effects as seen with other strong P-gp inhibitors. Apixaban Interaction not studied with any of Co-administration of apixaban, Rivaroxaban the components of Genvoya. rivaroxaban or edoxaban is not Edoxaban recommended with Genvoya. Co-administration with Genvoya may result in increased plasma concentrations of the DOAC, which may lead to an increased bleeding risk. Warfarin Interaction not studied with any of It is recommended that the the components of Genvoya. international normalised ratio (INR) be monitored upon Concentrations of warfarin may be co-administration of Genvoya. INR affected upon co-administration should continue to be monitored with Genvoya. during the first weeks following ceasing treatment with Genvoya.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) rivaroxaban (HOS-086236) lead (HOS-085592) edoxaban (HOS-086234) apixaban (HOS-112091) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage ba018832ef365523b9a535a7f7aa5dfc85e914f7b6d041422e168fd60038357d · Zeichen 35353–37013 im Abschnitt